Giant Cell Glioblastoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: GNT002 MIFTS: 57	Giant Cell Glioblastoma Categories: Cancer diseases, Neuronal diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Giant Cell Glioblastoma

MalaCards integrated aliases for Giant Cell Glioblastoma:

Name: Giant Cell Glioblastoma ¹¹ ⁵⁸ ⁵³ ⁵ ¹⁴ ⁷¹

Monstrocellular Sarcoma ¹¹ ⁷¹

Giant-Cell Glioblastoma ⁷⁵

Characteristics:

Prevelance:

<1/1000000 (Europe) ⁵⁸

Age Of Onset:

Adult ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

Malignant neoplasms of eye, brain and other parts of central nervous system

Malignant neoplasm of brain

Malignant neoplasm: Brain, unspecified

Orphanet: ⁵⁸

Rare neurological diseases

External Ids:

Disease Ontology ¹¹ DOID:3074

MeSH ⁴³ D005909

NCIt ⁴⁹ C4325

SNOMED-CT ⁶⁸ 44529004

ICD10 via Orphanet ³² C71.9

UMLS via Orphanet ⁷² C0334588

Orphanet ⁵⁸ ORPHA251579

UMLS ⁷¹ C0334588 C0334593

Sources

Summaries for Giant Cell Glioblastoma

Disease Ontology: ¹¹ A glioblastoma that is characterized by a prevalence of bizarre, multinucleated giant cells.

MalaCards based summary: Giant Cell Glioblastoma, also known as monstrocellular sarcoma, is related to glioma susceptibility 1 and sarcoma, and has symptoms including headache and seizures. An important gene associated with Giant Cell Glioblastoma is MSH2 (MutS Homolog 2), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and ERK Signaling. The drugs Temozolomide and Sargramostim have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and endothelial, and related phenotypes are Decreased viability and Increased shRNA abundance (Z-score > 2)

Wikipedia: ⁷⁵ The giant-cell glioblastoma is a histological variant of glioblastoma, presenting a prevalence of... more...

Sources

Related Diseases for Giant Cell Glioblastoma

Diseases related to Giant Cell Glioblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 377)

#	Related Disease	Score	Top Affiliating Genes
1	glioma susceptibility 1	31.6	TP53 LZTR1 IDH1 H3-3A
2	sarcoma	31.1	TP53 PIK3CA HRAS FGFR1 BRAF
3	glioblastoma	30.9	TP53 PTEN POLE PIK3R1 PIK3CA MYCN
4	pleomorphic xanthoastrocytoma	30.9	TP53 MGMT IDH1 H3-3A BRAF
5	neurofibromatosis, type i	30.7	TP53 PTEN MSH2 IDH1 HRAS EGFR
6	neurofibromatosis	30.6	TP53 PTEN MSH2 LZTR1 HRAS EGFR
7	diffuse astrocytoma	30.6	TP53 PTEN MGMT IDH1 H3-3A EGFR
8	glioma	30.6	TP53 PTEN PIK3CA MGMT IDH1 EGFR
9	anaplastic astrocytoma	30.6	TP53 PTEN MGMT IDH1 H3-3A EGFR
10	hydrocephalus	30.5	TP53 PTEN FGFR3 FGFR1
11	anaplastic pleomorphic xanthoastrocytoma	30.5	MGMT IDH1 H3-3A
12	papilloma	30.5	TP53 PTEN FGFR3 EGFR
13	high grade glioma	30.5	TP53 PTEN PIK3CA MGMT EGFR ATM
14	gemistocytic astrocytoma	30.5	TP53 PTEN MGMT IDH1
15	ganglioglioma	30.4	TP53 MYCN H3-3A BRAF
16	atypical teratoid rhabdoid tumor	30.4	TP53 MYCN IDH1 H3-3A EGFR
17	central nervous system cancer	30.4	TP53 MGMT IDH1 EGFR
18	malignant astrocytoma	30.4	TP53 PTEN MGMT IDH1 EGFR
19	idh-wildtype glioblastoma	30.3	TP53 PTEN MGMT IDH1 H3-3A EGFR
20	brain cancer	30.3	TP53 PTEN PIK3R1 PIK3CA MYCN MSH2
21	meningioma, familial	30.1	TP53 PTEN PIK3R1 PIK3CA MGMT LZTR1
22	medulloblastoma	29.9	TP53 PTEN PIK3CA MYCN MSH2 MGMT
23	gliosarcoma	29.6	TP53 TACC3 TACC1 SEPTIN14 PTEN POLE
24	rosette-forming glioneuronal tumor	10.5	PIK3CA FGFR1
25	high-grade astrocytoma	10.5	TP53 PTEN
26	plagiocephaly	10.5	FGFR3 FGFR1
27	simple partial epilepsy	10.5	PIK3CA IDH1 FGFR1
28	adult oligodendroglioma	10.4	IDH1 H3-3A FGFR1
29	cellular ependymoma	10.4	MSH2 MGMT EGFR
30	esophagus verrucous carcinoma	10.4	TP53 PIK3CA EGFR
31	verrucous carcinoma	10.4	TP53 PIK3CA EGFR
32	histoplasmosis meningitis	10.4	MGMT IDH1
33	neurofibrosarcoma	10.4	TP53 TACC1 FGFR1
34	adult brain stem glioma	10.4	MGMT IDH1 H3-3A
35	glottis squamous cell carcinoma	10.4	PTEN EGFR
36	urethra transitional cell carcinoma	10.4	TP53 EGFR BRAF
37	brain glioblastoma multiforme	10.4	TP53 MGMT EGFR
38	idh-wildtype anaplastic astrocytoma	10.4	MGMT IDH1 H3-3A
39	apocrine adenocarcinoma	10.4	TP53 PIK3CA EGFR
40	papillary adenofibroma	10.4	PTEN POLE MSH2
41	juvenile pilocytic astrocytoma	10.4	TP53 IDH1 H3-3A
42	chondroblastic osteosarcoma	10.4	TP53 IDH1 H3-3A
43	pancreatic signet ring cell adenocarcinoma	10.4	TP53 MSH2 HRAS
44	signet ring cell adenocarcinoma	10.4	TP53 MSH2 HRAS
45	astrocytoma, idh-mutant, grade 4	10.4	MGMT IDH1 H3-3A
46	fibrillary astrocytoma	10.4	TP53 IDH1 H3-3A
47	neuroma	10.4	MSH2 MGMT LZTR1 FGFR1
48	small intestine adenocarcinoma	10.4	TP53 MSH2 HRAS
49	spinal cancer	10.4	LZTR1 IDH1 H3-3A
50	anal squamous cell carcinoma	10.4	TP53 PIK3CA EGFR

Graphical network of the top 20 diseases related to Giant Cell Glioblastoma:

Sources

Symptoms & Phenotypes for Giant Cell Glioblastoma

UMLS symptoms related to Giant Cell Glioblastoma:

headache; seizures

GenomeRNAi Phenotypes related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

²⁵ (show all 40)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	10.61	BRAF EGFR HRAS PIK3CA
2	Decreased viability	GR00055-A-2	10.61	BRAF EGFR HRAS PIK3CA
3	Decreased viability	GR00221-A-1	10.61	EGFR HRAS PIK3CA FGFR1 FGFR3 PIK3R1
4	Decreased viability	GR00221-A-2	10.61	HRAS PIK3CA FGFR1 FGFR3
5	Decreased viability	GR00221-A-3	10.61	HRAS FGFR3 PIK3R1
6	Decreased viability	GR00221-A-4	10.61	BRAF EGFR PIK3CA
7	Decreased viability	GR00249-S	10.61	BRAF FGFR3
8	Decreased viability	GR00301-A	10.61	BRAF
9	Decreased viability	GR00381-A-1	10.61	BRAF
10	Decreased viability	GR00386-A-1	10.61	FGFR1
11	Decreased viability	GR00402-S-2	10.61	PIK3CA
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-100	10.35	FGFR1
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-102	10.35	PIK3R1
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-116	10.35	MSH2
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-121	10.35	EGFR
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-125	10.35	FGFR1
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-14	10.35	MSH2
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-151	10.35	MSH2
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-169	10.35	FGFR1
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-176	10.35	MSH2
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-177	10.35	PIK3R1
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-183	10.35	FGFR1
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-196	10.35	HRAS
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-199	10.35	PIK3R1
25	Increased shRNA abundance (Z-score > 2)	GR00366-A-21	10.35	EGFR
26	Increased shRNA abundance (Z-score > 2)	GR00366-A-214	10.35	EGFR MSH2 PIK3R1
27	Increased shRNA abundance (Z-score > 2)	GR00366-A-26	10.35	FGFR1
28	Increased shRNA abundance (Z-score > 2)	GR00366-A-28	10.35	HRAS
29	Increased shRNA abundance (Z-score > 2)	GR00366-A-34	10.35	PIK3R1
30	Increased shRNA abundance (Z-score > 2)	GR00366-A-43	10.35	EGFR FGFR1 PIK3R1
31	Increased shRNA abundance (Z-score > 2)	GR00366-A-47	10.35	FGFR1
32	Increased shRNA abundance (Z-score > 2)	GR00366-A-50	10.35	FGFR1
33	Increased shRNA abundance (Z-score > 2)	GR00366-A-53	10.35	MSH2
34	Increased shRNA abundance (Z-score > 2)	GR00366-A-83	10.35	FGFR1 HRAS
35	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	10.35	EGFR
36	Increased shRNA abundance (Z-score > 2)	GR00366-A-87	10.35	HRAS
37	Increased shRNA abundance (Z-score > 2)	GR00366-A-91	10.35	EGFR
38	no effect	GR00402-S-1	10.19	ATM BRAF EGFR FGFR1 FGFR3 H3-3A
39	no effect	GR00402-S-2	10.19	ATM BRAF EGFR FGFR1 FGFR3 H3-3A
40	Reduced mammosphere formation	GR00396-S	9.5	ATM BRAF EGFR HRAS PIK3R1 POLE

MGI Mouse Phenotypes related to Giant Cell Glioblastoma:

⁴⁵ (show all 22)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	nervous system	MP:0003631	10.43	ATM BRAF EGFR FGFR1 FGFR3 HRAS
2	neoplasm	MP:0002006	10.42	ATM BRAF EGFR FGFR3 HRAS MGMT
3	homeostasis/metabolism	MP:0005376	10.41	ATM BRAF EGFR FGFR1 FGFR3 H3-3A
4	growth/size/body region	MP:0005378	10.4	ATM BRAF EGFR FGFR1 FGFR3 H3-3A
5	normal	MP:0002873	10.34	BRAF EGFR FGFR1 FGFR3 H3-3A HRAS
6	cellular	MP:0005384	10.28	ATM BRAF EGFR FGFR1 FGFR3 H3-3A
7	muscle	MP:0005369	10.27	BRAF EGFR FGFR1 HRAS LZTR1 MYCN
8	endocrine/exocrine gland	MP:0005379	10.25	ATM BRAF EGFR FGFR1 HRAS MGMT
9	renal/urinary system	MP:0005367	10.23	BRAF EGFR FGFR1 FGFR3 H3-3A HRAS
10	no phenotypic analysis	MP:0003012	10.19	EGFR FGFR1 FGFR3 HRAS MGMT MYCN
11	embryo	MP:0005380	10.19	ATM BRAF EGFR FGFR1 H3-3A MYCN
12	digestive/alimentary	MP:0005381	10.18	BRAF EGFR FGFR1 FGFR3 HRAS MSH2
13	immune system	MP:0005387	10.18	ATM BRAF EGFR FGFR1 FGFR3 IDH1
14	limbs/digits/tail	MP:0005371	10.16	BRAF EGFR FGFR1 FGFR3 MYCN PTEN
15	cardiovascular system	MP:0005385	10.14	ATM BRAF EGFR FGFR1 HRAS LZTR1
16	craniofacial	MP:0005382	10.11	BRAF EGFR FGFR1 FGFR3 HRAS LZTR1
17	adipose tissue	MP:0005375	10.09	ATM BRAF EGFR PIK3CA PIK3R1 PTEN
18	skeleton	MP:0005390	10.03	BRAF EGFR FGFR1 FGFR3 HRAS IDH1
19	hematopoietic system	MP:0005397	10	ATM BRAF EGFR FGFR1 FGFR3 IDH1
20	respiratory system	MP:0005388	9.97	BRAF EGFR FGFR3 HRAS IDH1 MGMT
21	mortality/aging	MP:0010768	9.91	ATM BRAF EGFR FGFR1 FGFR3 H3-3A
22	integument	MP:0010771	9.4	ATM BRAF EGFR FGFR1 FGFR3 HRAS

Sources

Drugs & Therapeutics for Giant Cell Glioblastoma

Drugs for Giant Cell Glioblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 148)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Temozolomide

Approved, Investigational

Phase 3

85622-93-1

5394

Sargramostim

Approved, Investigational

Phase 3

123774-72-1

Molgramostim

Investigational

Phase 3

99283-10-0

Rindopepimut

Investigational

Phase 3

1108208-65-6

Alkylating Agents

Phase 3

Antineoplastic Agents, Alkylating

Phase 3

Immunologic Factors

Phase 3

Antineoplastic Agents, Immunological

Phase 3

Erlotinib

Approved, Investigational

Phase 1, Phase 2

183319-69-9, 183321-74-6

176870

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239

Dasatinib

Approved, Investigational

Phase 2

302962-49-8

3062316

Aflibercept

Approved

Phase 2

862111-32-8

124490314

Acetic acid

Approved

Phase 2

64-19-7

176

Plerixafor

Approved

Phase 1, Phase 2

110078-46-1

65015

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 2

23593-75-1

2812

Romidepsin

Approved, Investigational

Phase 1, Phase 2

128517-07-7

5352062

Gefitinib

Approved, Investigational

Phase 2

184475-35-2

123631

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

5284616 6436030

Lapatinib

Approved, Investigational

Phase 1, Phase 2

231277-92-2, 388082-78-8

208908

Basiliximab

Approved, Investigational

Phase 2

179045-86-4

Cyclophosphamide

Approved, Investigational

Phase 1, Phase 2

50-18-0, 6055-19-2

2907

Fludarabine

Approved

Phase 1, Phase 2

75607-67-9, 21679-14-1

30751 657237

Aldesleukin

Approved

Phase 1, Phase 2

110942-02-4

Coenzyme M

Approved, Investigational

Phase 1, Phase 2

3375-50-6

598 23662354

Bevacizumab

Approved, Investigational

Phase 1, Phase 2

216974-75-3

135329020

Aminolevulinic acid

Approved

Phase 2

106-60-5

137

Lopinavir

Approved

Phase 2

192725-17-0

92727

Ritonavir

Approved, Investigational

Phase 2

155213-67-5

392622

Oxaliplatin

Approved, Investigational

Phase 1, Phase 2

61825-94-3

43805 11947679 6857599

Vitamin A

Approved, Nutraceutical, Vet_approved

Phase 2

22737-96-8, 68-26-8

5280382 445354

D-Tyrosine

Approved, Experimental, Investigational, Nutraceutical

Phase 1, Phase 2

133585-56-5, 60-18-4, 556-02-5

1153 6057

Aspartic acid

Approved, Nutraceutical

Phase 1, Phase 2

56-84-8

5960

Arginine

Approved, Investigational, Nutraceutical

Phase 1, Phase 2

74-79-3

6322

Glycine

Approved, Nutraceutical, Vet_approved

Phase 1, Phase 2

56-40-6

750

Veliparib

Investigational

Phase 1, Phase 2

912444-00-9

11960529

Cediranib

Investigational

Phase 1, Phase 2

288383-20-0

9933475

Maleic acid

Experimental, Investigational

Phase 1, Phase 2

110-16-7, 110-17-8

444266 444972

(-)-Gossypol

Investigational

Phase 2

303-45-7, 90141-22-3

3503

Zuretinol acetate

Investigational

Phase 2

127-47-9, 29584-22-3

10245972

Trebananib

Investigational

Phase 2

894356-79-7

Tipifarnib

Investigational

Phase 2

192185-72-1

159324

Motexafin gadolinium

Investigational

Phase 1, Phase 2

246252-06-2

Misonidazole

Investigational

Phase 2

13551-87-6

26105

Imetelstat

Investigational

Phase 2

868169-64-6

Fenretinide

Investigational

Phase 2

65646-68-6

5288209

Neurotransmitter Agents

Phase 1, Phase 2

Radiopharmaceuticals

Phase 1, Phase 2

Poly(ADP-ribose) Polymerase Inhibitors

Phase 1, Phase 2

Antimetabolites

Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 100)

#	Name	Status	NCT ID	Phase	Drugs
1	An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma	Completed	NCT01480479	Phase 3	Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
2	Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma	Unknown status	NCT01730950	Phase 2
3	A Phase I/II Study of ABT-888, An Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG)	Completed	NCT01514201	Phase 1, Phase 2	Temozolomide;Veliparib
4	A Phase Ib/II Study of AZD2171 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma Not Taking Enzyme-Inducing Anti-epileptic Drugs	Completed	NCT00662506	Phase 1, Phase 2	Cediranib Maleate;Temozolomide
5	A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients With Progression or Recurrent Glioblastoma Multiforme	Completed	NCT00445588	Phase 2	erlotinib hydrochloride;sorafenib tosylate
6	Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme	Completed	NCT00423735	Phase 2	Dasatinib
7	A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients With Recurrent Glioblastoma	Completed	NCT00379080	Phase 1, Phase 2	tandutinib
8	Phase II Study of Vorinostat (SAHA) in Combination With Bortezomib (PS-341) in Patients With Recurrent Glioblastoma Multiforme	Completed	NCT00641706	Phase 2	vorinostat;bortezomib
9	A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma)	Completed	NCT00823797	Phase 2	Bendamustine Hydrochloride
10	Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma	Completed	NCT00731731	Phase 1, Phase 2	Temozolomide;Vorinostat
11	A Phase 2 Study of R-(-)-Gossypol (Ascenta's AT-101) in Recurrent Glioblastoma Multiforme	Completed	NCT00540722	Phase 2	R-(-)-gossypol acetic acid
12	A Phase I/II Study of Local Field Irradiation and Temozolomide Followed by Continuous Infusion Plerixafor as an Upfront Therapy for Newly Diagnosed Glioblastoma GBM	Completed	NCT01977677	Phase 1, Phase 2	temozolomide;plerixafor
13	A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas	Completed	NCT00499473	Phase 2	sunitinib malate
14	A Phase II Trial of GW786034 (Pazopanib) in Patients With Recurrent Glioblastoma	Completed	NCT00459381	Phase 2	pazopanib hydrochloride
15	A Prospective Phase II Trial of NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma	Completed	NCT01894061	Phase 2
16	Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas	Completed	NCT00369590	Phase 2
17	A Phase I-II Trial of Depsipeptide in Patients With Recurrent High-Grade Gliomas	Completed	NCT00085540	Phase 1, Phase 2	depsipeptide
18	Phase II Study Of ZD1839 (NSC 715055) In Newly Diagnosed Patients With Glioblastoma (Grade 4 Astrocytoma)	Completed	NCT00014170	Phase 2	gefitinib
19	A Phase II Study of CCI-779 in Patients With Recurrent Glioblastoma Multiforme	Completed	NCT00016328	Phase 2	temsirolimus
20	Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma	Completed	NCT01609790	Phase 2
21	Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients With Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma	Completed	NCT00095940	Phase 1, Phase 2	lapatinib ditosylate
22	Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirolimus) in Patients With Recurrent Malignant Glioma	Completed	NCT00112736	Phase 1, Phase 2	erlotinib;temsirolimus
23	Phase II Study of R115777 for the Treatment of Adults With Newly Diagnosed Glioblastoma Multiforme	Completed	NCT00058097	Phase 2	tipifarnib
24	A Phase I/II Study of an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), ZD 1839 (Iressa), [NSC #715055] With Radiation Therapy in Glioblastoma Multiforme	Completed	NCT00052208	Phase 1, Phase 2	gefitinib
25	Phase I/II Trial of Gefitinib and Radiation in Pediatric Patients Newly Diagnosed With Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas With Phase II Limited to Brain Stem Tumors	Completed	NCT00042991	Phase 1, Phase 2	gefitinib
26	Evaluation of Overcoming Limited Migration and Enhancing Cytomegalovirus-specific Dendritic Cell Vaccines With Adjuvant TEtanus Pre-conditioning in Patients With Newly-diagnosed Glioblastoma	Completed	NCT02366728	Phase 2	Temozolomide;Saline;Basiliximab
27	Phase I/II Trial of Temsirolimus and Perifosine for Recurrent or Progressive Malignant Gliomas	Completed	NCT01051557	Phase 1, Phase 2	Perifosine;Temsirolimus
28	A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy	Completed	NCT00045110	Phase 1, Phase 2	erlotinib hydrochloride
29	A Pilot and Phase II Study of OSI-774 and Temozolomide in Combination With Radiation Therapy in Glioblastoma Multiforme	Completed	NCT00039494	Phase 2	erlotinib hydrochloride;temozolomide
30	A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme	Completed	NCT00980343	Phase 2	vismodegib
31	Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma	Completed	NCT00335764	Phase 1, Phase 2	sorafenib tosylate;erlotinib hydrochloride;tipifarnib;temsirolimus
32	A PHASE I/II TRIAL OF TEMOZOLOMIDE, MOTEXAFIN GADOLINIUM, AND 60 GY FRACTIONATED RADIATION FOR NEWLY DIAGNOSED SUPRATENTORIAL GLIOBLASTOMA MULTIFORME	Completed	NCT00305864	Phase 1, Phase 2	Motexafin Gadolinium;Temozolomide
33	A Phase II Study of AZD2171 in Recurrent Glioblastoma	Completed	NCT00305656	Phase 2	cediranib maleate
34	Phase II Trial of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Recurrent Glioblastoma	Completed	NCT00238303	Phase 2	vorinostat
35	Phase II Clinical and Pharmacologic Study of Radiation Therapy and CAI (Carboxy-Amido Triazole) in Adults With Newly Diagnosed Glioblastoma Multiforme	Completed	NCT00004146	Phase 2	carboxyamidotriazole
36	Phase I/Comparative Randomized Phase II Trial of TRC105 Plus Bevacizumab Versus Bevacizumab in Bevacizumab-Naive Patients With Recurrent Glioblastoma Multiforme	Completed	NCT01648348	Phase 1, Phase 2
37	A Safety Run-in/Randomized Phase II Trial of EMD 121974 in Conjunction With Concomitant and Adjuvant Temozolomide With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme	Completed	NCT00085254	Phase 1, Phase 2	cilengitide;temozolomide
38	A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-grade Gliomas	Completed	NCT00045708	Phase 1, Phase 2	ixabepilone;Anticonvulsant
39	Multicenter, Phase II Assessment of Tumor Hypoxia in Glioblastoma Using 18F-Fluoromisonidazole (FMISO) With PET and MRI	Completed	NCT00902577	Phase 2	FMISO
40	Phase II Study of TKI258 (Dovitinib) in Patients With Recurrent or Progressive Glioblastoma Who Have Progressed With or Without Anti-Angiogenic Therapy (Including Anti-VEGF Therapy)	Completed	NCT01753713	Phase 2	dovitinib
41	Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis	Completed	NCT01806675	Phase 1, Phase 2	18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
42	A Phase II Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma	Completed	NCT01498328	Phase 2	Bevacizumab;Rindopepimut (CDX-110) with GM-CSF;KLH
43	Phase II Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma	Recruiting	NCT03027388	Phase 2	LB-100
44	A Phase I/IIa Open Label Multicenter, Non-Randomized, Trial to Assess the Safety and Efficacy of CYNK-001in Combination With Recombinant Human Interleukin-2 in Adults With Recurrent Resection Eligible IDH1 Wild-type Glioblastoma	Recruiting	NCT05218408	Phase 1, Phase 2
45	Phase II Study of Bevacizumab and Temozolomide in Elderly Patients With Newly-Diagnosed Glioblastoma	Active, not recruiting	NCT01149850	Phase 2	temozolomide
46	Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma	Active, not recruiting	NCT02179086	Phase 2	temozolomide
47	Phase II Clinical Trial of HSV G207 With a Single 5 Gy Radiation Dose in Children With Recurrent High-Grade Glioma	Not yet recruiting	NCT04482933	Phase 2	Biological G207
48	A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma	Terminated	NCT01836549	Phase 2	imetelstat sodium
49	Phase II Trial of Ritonavir/Lopinavir in Patients With Progressive of Recurrent High-Grade Gliomas	Terminated	NCT01095094	Phase 2	ritonavir;lopinavir
50	A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma	Terminated	NCT01122901	Phase 2	gamma-secretase/Notch signalling pathway inhibitor RO4929097

Search NIH Clinical Center for Giant Cell Glioblastoma

Sources

Genetic Tests for Giant Cell Glioblastoma

Sources

Anatomical Context for Giant Cell Glioblastoma

Organs/tissues related to Giant Cell Glioblastoma:

MalaCards : Brain, Eye, Endothelial, Liver, Medulla Oblongata, Cerebellum, Cortex

Sources

Publications for Giant Cell Glioblastoma

Articles related to Giant Cell Glioblastoma:

(show top 50) (show all 142)

#	Title	Authors	PMID	Year
1	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. ⁵	Chang MT...Taylor BS	26619011	2016
2	Genetic profile of the giant cell glioblastoma. ⁵³ ⁶²	Peraud A...Ohgaki H	10068201	1999
3	p53 mutations versus EGF receptor expression in giant cell glioblastomas. ⁵³ ⁶²	Peraud A...Ohgaki H	9370234	1997
4	Gliosarcoma with unusual glial components: Two case reports. ⁶²	Otsu Y...Sugita Y	35644835	2022
5	Morphogenetic and Imaging Characteristics in Giant Cell Glioblastoma. ⁶²	Orasanu CI...Cozaru GC	36005160	2022
6	Glioblastoma: Changing concepts in the WHO CNS5 classification. ⁶²	Chen J...Dahiya S	35562131	2022
7	Case report: Awake craniotomy during pregnancy for resection of glioblastoma. ⁶²	Gunasekaran A...Rowland NC	35367747	2022
8	IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation. ⁶²	Barresi V...Scarpa A	34952640	2021
9	SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma. ⁶²	Brosnan-Cashman JA...Heaphy CM	34103668	2021
10	Cyclin D1 expression in ganglioglioma, pleomorphic xanthoastrocytoma and pilocytic astrocytoma. ⁶²	Forest F...Peoc'h M	34022185	2021
11	Differentiating Giant Cell Glioblastoma from Classic Glioblastoma With Diffusion-Weighted Imaging. ⁶²	Xue C...Zhou J	33127573	2021
12	Primary Intracranial Leiomyosarcoma Secondary to Glioblastoma: Case Report and Literature Review. ⁶²	Zhao L...Li Y	34094927	2021
13	Epidemiologic Features, Survival, and Prognostic Factors Among Patients With Different Histologic Variants of Glioblastoma: Analysis of a Nationwide Database. ⁶²	Shieh LT...Ho SY	34899553	2021
14	Pediatric Giant Cell Glioblastoma Presenting with Intracranial Dissemination at Diagnosis: A Case Report. ⁶²	Kinoshita T...Iwama T	35079457	2021
15	Giant cell glioblastoma multiforme presents as acute pathological nontraumatic subdural haematoma. ⁶²	Al-Mousa A...Shtaya A	33369511	2020
16	Giant cell glioblastoma in 6-year-old kid: Report of an unusual case. ⁶²	Shrestha S...Shrivastav S	33363854	2020
17	Characterization and Histological Examination of a Rare Giant Cell Glioblastoma. ⁶²	Reddy SV...Liuzzi FJ	32821583	2020
18	Update on Circumscribed Gliomas and Glioneuronal Tumors. ⁶²	Chen J...Dahiya SM	32389265	2020
19	Near haploidization is a genomic hallmark which defines a molecular subgroup of giant cell glioblastoma. ⁶²	Baker TG...Meredith DM	33392505	2020
20	TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors. ⁶²	Cantero D...Hernandez-Lain A	32642724	2020
21	Giant cell glioblastoma is a distinctive subtype of glioma characterized by vulnerability to DNA damage. ⁶²	Ogawa K...Kurotaki H	31655917	2020
22	Whole-exome sequencing revealed mutational profiles of giant cell glioblastomas. ⁶²	Shi ZF...Ng HK	30861589	2019
23	Association between giant cell glioblastoma and glioblastoma multiforme in the United States: A retrospective cohort study. ⁶²	Bin Abdulrahman AK...Ruiz JG	31464386	2019
24	Prognostic Factors and Treatment Patterns in the Management of Giant Cell Glioblastoma. ⁶²	Jin MC...Pollom EL	31009783	2019
25	Germline mutation p.N363K in POLE is associated with an increased risk of colorectal cancer and giant cell glioblastoma. ⁶²	Vande Perre P...Guimbaud R	30368636	2019
26	Subgaleal and brain abscesses due to Salmonella enteritidis following craniotomy for giant cell glioblastoma multiforme: A case report and literature review. ⁶²	Akhaddar A...Boucetta M	31528375	2019
27	An Unusual Presentation of Spinal Giant Cell Glioblastoma in a 21-Year-Old Female. ⁶²	Delgado BJ...Cobos E	31394931	2019
28	Imaging findings in the progression of a giant cell glioblastoma. ⁶²	Turner R...Gelman B	30128062	2018
29	Giant cell glioblastoma with spinal and spinal leptomeningeal metastasis in a child: A rare presentation of a rare tumor. ⁶²	Al-Mendalawi MD	30783357	2018
30	Glioblastoma in the setting of prior lower grade gliomas - insights from SEER database. ⁶²	Nguyen HS...Mortazavi MM	30279958	2018
31	Giant cell glioblastoma with spinal and spinal leptomeningeal metastasis in a child: A rare presentation of a rare tumor. ⁶²	Biswas R...Rath GK	30443141	2018
32	Acute lymphoblastic leukemia following temozolomide treatment in a patient with glioblastoma: A case report and review of the literature. ⁶²	Liu P...Mu Q	29805603	2018
33	Risk of subsequent cancer among pediatric, adult and elderly patients following a primary diagnosis of glioblastoma multiforme: a population-based study of the SEER database. ⁶²	Li X...Feng E	28288541	2017
34	IDH-mutant giant cell glioblastoma: A neglected tumor variant? ⁶²	Leske H...Niehusmann P	29035191	2017
35	Giant Cell Glioblastoma in a Child with Clinical and Family History of Neurofibromatosis. ⁶²	Pant I...Chaturvedi S	29114311	2017
36	Intraventricular gliosarcoma with dual sarcomatous differentiation: A unique case. ⁶²	Poyuran R...Savardekar AR	28261869	2017
37	Radiologic Dilemma in an Extra-Axial Petroclival Lesion: Low Grade versus High Grade. ⁶²	Karthigeyan M...Salunke P	28109858	2017
38	Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma. ⁶²	Shabihkhani M...Yong WH	28161760	2017
39	Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma. ⁶²	Oh JE...Ohgaki H	26443480	2016
40	Intraoperative Squash Cytologic Features of Subependymal Giant Cell Astrocytoma. ⁶²	Nasit J...Patel S	27013816	2016
41	MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma. ⁶²	Lohkamp LN...Koch A	27253461	2016
42	Pediatric Giant Cell Glioblastoma Mimicking Hemorrhage Secondary to Ischemic Stroke. ⁶²	Stoecklein VM...Mueller S	26344331	2015
43	Giant cell glioblastoma with calcification and long-term survival. ⁶²	Mallya V...Sharma KC	26960525	2015
44	A spontaneously occurring malignant pituicytoma in a male sprague dawley rat. ⁶²	Moroki T...Doi T	26441479	2015
45	Adult classical glioblastoma with a BRAF V600E mutation. ⁶²	Takahashi Y...Kamada H	25885250	2015
46	Survival outcomes of giant cell glioblastoma: institutional experience in the management of 20 patients. ⁶²	Oh T...Parsa AT	25037316	2014
47	Treatment and survival of patients harboring histological variants of glioblastoma. ⁶²	Ortega A...Patil CG	24980627	2014
48	[Gliosarcoma of cerebral hemispheres: a clinicopathologic study of 10 cases]. ⁶²	Huo Z...Yang D	25567590	2014
49	Estimating the surface area of nonconvex particles from central planar sections. ⁶²	Thorisdottir O...Kiderlen M	24832486	2014
50	Cerebellar giant cell glioblastoma multiforme in an adult. ⁶²	Mishra SS...Senapati SB	25002780	2014

Sources

Genes for Giant Cell Glioblastoma

Genes related to Giant Cell Glioblastoma (13 elite genes):

(show all 46)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MSH2	MutS Homolog 2	Protein Coding	403.53	Pathogenic ⁵ DISEASES inferred ¹⁴
2	EGFR	Epidermal Growth Factor Receptor	Protein Coding	386.43	Gene fusion ⁵⁸ Likely pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³	24075187 24071942 26619011 (more) 9370234
3	FGFR1	Fibroblast Growth Factor Receptor 1	Protein Coding	378.38	Gene fusion ⁵⁸ Likely pathogenic ⁵ DISEASES inferred ¹⁴	22837387 26619011
4	FGFR3	Fibroblast Growth Factor Receptor 3	Protein Coding	353.7	Gene fusion ⁵⁸ DISEASES inferred ¹⁴	22837387
5	LZTR1	Leucine Zipper Like Transcription Regulator 1	Protein Coding	353.01	Causative somatic mutation ⁵⁸ DISEASES inferred ¹⁴	24075187 24071842
6	SEPTIN14	Septin 14	Protein Coding	352.84	Gene fusion ⁵⁸ DISEASES inferred ¹⁴	24075187 24071942
7	TACC1	Transforming Acidic Coiled-Coil Containing Protein 1	Protein Coding	350	Gene fusion ⁵⁸	22837387
8	TACC3	Transforming Acidic Coiled-Coil Containing Protein 3	Protein Coding	350	Gene fusion ⁵⁸	22837387
9	IDH1	Isocitrate Dehydrogenase (NADP(+)) 1	Protein Coding	56.34	Likely pathogenic ⁵ Orphanet ⁵⁸ DISEASES inferred ¹⁴	26619011 18772396
10	TP53	Tumor Protein P53	Protein Coding	55.89	Likely pathogenic ⁵ Orphanet ⁵⁸ DISEASES inferred ¹⁴	26619011 17785346
11	MGMT	O-6-Methylguanine-DNA Methyltransferase	Protein Coding	30.79	Orphanet ⁵⁸ DISEASES inferred ¹⁴	22380407 20556478
12	NFKBIA	NFKB Inhibitor Alpha	Protein Coding	25	Orphanet ⁵⁸	25215581
13	PPARG	Peroxisome Proliferator Activated Receptor Gamma	Protein Coding	25	Orphanet ⁵⁸	10851250
14	PTEN	Phosphatase And Tensin Homolog	Protein Coding	37.19	Likely pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³	26619011 10068201 9619835
15	H3-3A	H3.3 Histone A	Protein Coding	30.37	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
16	POLE	DNA Polymerase Epsilon, Catalytic Subunit	Protein Coding	30.01	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
17	PIK3R1	Phosphoinositide-3-Kinase Regulatory Subunit 1	Protein Coding	29.42	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
18	MYCN	MYCN Proto-Oncogene, BHLH Transcription Factor	Protein Coding	29.1	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
19	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	29.09	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
20	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	28.53	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
21	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	27.92	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
22	ATM	ATM Serine/Threonine Kinase	Protein Coding	25	Likely pathogenic ⁵
23	C11orf65	Chromosome 11 Open Reading Frame 65	Protein Coding	25	Likely pathogenic ⁵
24	CREBBP	CREB Binding Protein	Protein Coding	25	Likely pathogenic ⁵	26619011
25	DNMT3A	DNA Methyltransferase 3 Alpha	Protein Coding	25	Likely pathogenic ⁵
26	FBXW7	F-Box And WD Repeat Domain Containing 7	Protein Coding	25	Likely pathogenic ⁵	26619011
27	LRRC56	Leucine Rich Repeat Containing 56	Protein Coding	25	Likely pathogenic ⁵	26619011
28	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	25	Likely pathogenic ⁵	26619011
29	MYCNOS	MYCN Opposite Strand	RNA Gene	25	Likely pathogenic ⁵	26619011
30	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	25	Likely pathogenic ⁵	26619011
31	GFAP	Glial Fibrillary Acidic Protein	Protein Coding	13.15	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16718521
32	MDM2	MDM2 Proto-Oncogene	Protein Coding	10.67	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10068201
33	SERPINA3	Serpin Family A Member 3	Protein Coding	7.27	DISEASES inferred ¹⁴ ¹⁴
34	ATRX	ATRX Chromatin Remodeler	Protein Coding	5.86	DISEASES inferred ¹⁴
35	H3-3B	H3.3 Histone B	Protein Coding	5.38	DISEASES inferred ¹⁴
36	TERT	Telomerase Reverse Transcriptase	Protein Coding	5.37	DISEASES inferred ¹⁴
37	IDH2	Isocitrate Dehydrogenase (NADP(+)) 2	Protein Coding	5.36	DISEASES inferred ¹⁴
38	NF1	Neurofibromin 1	Protein Coding	5.33	DISEASES inferred ¹⁴
39	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	5.29	DISEASES inferred ¹⁴
40	OLIG2	Oligodendrocyte Transcription Factor 2	Protein Coding	5.26	DISEASES inferred ¹⁴
41	SYP	Synaptophysin	Protein Coding	5.18	DISEASES inferred ¹⁴
42	PDGFRA	Platelet Derived Growth Factor Receptor Alpha	Protein Coding	4.96	DISEASES inferred ¹⁴
43	H3C6	H3 Clustered Histone 6	Protein Coding	4.88	DISEASES inferred ¹⁴
44	H3C3	H3 Clustered Histone 3	Protein Coding	4.88	DISEASES inferred ¹⁴
45	H3C4	H3 Clustered Histone 4	Protein Coding	4.88	DISEASES inferred ¹⁴
46	H3C11	H3 Clustered Histone 11	Protein Coding	4.8	DISEASES inferred ¹⁴

Sources

Variations for Giant Cell Glioblastoma

ClinVar genetic disease variations for Giant Cell Glioblastoma:

⁵ (show top 50) (show all 233)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	H3-3A	NM_002107.7(H3-3A):c.103G>A (p.Gly35Arg)	SNV	Other	438766	rs1553260624	GRCh37: 1:226252155-226252155 GRCh38: 1:226064454-226064454
2	MED12	NM_005120.3(MED12):c.5980C>T (p.Arg1994Trp)	SNV	Other	438772	rs1556339256	GRCh37: X:70357729-70357729 GRCh38: X:71137879-71137879
3	BCOR	NM_001123385.2(BCOR):c.3883_3884del (p.Leu1296fs)	MICROSAT	Other	284290	rs886042842	GRCh37: X:39922288-39922289 GRCh38: X:40063035-40063036
4	MSH2	NM_000251.3(MSH2):c.1958_1965del (p.Asn653fs)	DEL	Pathogenic	590849	rs1558518449	GRCh37: 2:47702360-47702367 GRCh38: 2:47475221-47475228
5	NRAS	NM_002524.5(NRAS):c.181C>A (p.Gln61Lys)	SNV	Likely Pathogenic	73058	rs121913254	GRCh37: 1:115256530-115256530 GRCh38: 1:114713909-114713909
6	TP53	NM_000546.6(TP53):c.641A>T (p.His214Leu)	SNV	Likely Pathogenic	376616	rs1057519992	GRCh37: 17:7578208-7578208 GRCh38: 17:7674890-7674890
7	PIK3CA	NM_006218.4(PIK3CA):c.241G>A (p.Glu81Lys)	SNV	Likely Pathogenic	376478	rs1057519929	GRCh37: 3:178916854-178916854 GRCh38: 3:179199066-179199066
8	HRAS, LRRC56	NM_005343.4(HRAS):c.34G>T (p.Gly12Cys)	SNV	Likely Pathogenic	12613	rs104894229	GRCh37: 11:534289-534289 GRCh38: 11:534289-534289
9	NRAS	NM_002524.5(NRAS):c.182A>G (p.Gln61Arg)	SNV	Likely Pathogenic	13900	rs11554290	GRCh37: 1:115256529-115256529 GRCh38: 1:114713908-114713908
10	HRAS, LRRC56	NM_005343.4(HRAS):c.35G>C (p.Gly12Ala)	SNV	Likely Pathogenic	12603	rs104894230	GRCh37: 11:534288-534288 GRCh38: 11:534288-534288
11	IDH1	NM_005896.4(IDH1):c.395G>A (p.Arg132His)	SNV	Likely Pathogenic	156444	rs121913500	GRCh37: 2:209113112-209113112 GRCh38: 2:208248388-208248388
12	TP53	NM_000546.6(TP53):c.659A>G (p.Tyr220Cys)	SNV	Likely Pathogenic	127819	rs121912666	GRCh37: 17:7578190-7578190 GRCh38: 17:7674872-7674872
13	TP53	NM_000546.6(TP53):c.584T>A (p.Ile195Asn)	SNV	Likely Pathogenic	376618	rs760043106	GRCh37: 17:7578265-7578265 GRCh38: 17:7674947-7674947
14	TP53	NM_000546.6(TP53):c.374C>T (p.Thr125Met)	SNV	Likely Pathogenic	183748	rs786201057	GRCh37: 17:7579313-7579313 GRCh38: 17:7675995-7675995
15	TP53	NM_000546.6(TP53):c.722C>G (p.Ser241Cys)	SNV	Likely Pathogenic	177791	rs28934573	GRCh37: 17:7577559-7577559 GRCh38: 17:7674241-7674241
16	TP53	NM_000546.6(TP53):c.730G>T (p.Gly244Cys)	SNV	Likely Pathogenic	376599	rs1057519989	GRCh37: 17:7577551-7577551 GRCh38: 17:7674233-7674233
17	TP53	NM_000546.6(TP53):c.742C>T (p.Arg248Trp)	SNV	Likely Pathogenic	12347	rs121912651	GRCh37: 17:7577539-7577539 GRCh38: 17:7674221-7674221
18	TP53	NM_000546.6(TP53):c.796G>C (p.Gly266Arg)	SNV	Likely Pathogenic	376605	rs1057519990	GRCh37: 17:7577142-7577142 GRCh38: 17:7673824-7673824
19	TP53	NM_000546.6(TP53):c.712T>C (p.Cys238Arg)	SNV	Likely Pathogenic	376576	rs1057519981	GRCh37: 17:7577569-7577569 GRCh38: 17:7674251-7674251
20	TP53	NM_000546.6(TP53):c.374C>G (p.Thr125Arg)	SNV	Likely Pathogenic	376667	rs786201057	GRCh37: 17:7579313-7579313 GRCh38: 17:7675995-7675995
21	TP53	NM_000546.6(TP53):c.535C>T (p.His179Tyr)	SNV	Likely Pathogenic	127815	rs587780070	GRCh37: 17:7578395-7578395 GRCh38: 17:7675077-7675077
22	TP53	NM_000546.6(TP53):c.580C>T (p.Leu194Phe)	SNV	Likely Pathogenic	127817	rs587780071	GRCh37: 17:7578269-7578269 GRCh38: 17:7674951-7674951
23	TP53	NM_000546.6(TP53):c.658T>C (p.Tyr220His)	SNV	Likely Pathogenic	376687	rs530941076	GRCh37: 17:7578191-7578191 GRCh38: 17:7674873-7674873
24	TP53	NM_000546.6(TP53):c.637C>G (p.Arg213Gly)	SNV	Likely Pathogenic	376651	rs397516436	GRCh37: 17:7578212-7578212 GRCh38: 17:7674894-7674894
25	TP53	NM_000546.6(TP53):c.817C>A (p.Arg273Ser)	SNV	Likely Pathogenic	376656	rs121913343	GRCh37: 17:7577121-7577121 GRCh38: 17:7673803-7673803
26	TP53	NM_000546.6(TP53):c.733G>A (p.Gly245Ser)	SNV	Likely Pathogenic	12365	rs28934575	GRCh37: 17:7577548-7577548 GRCh38: 17:7674230-7674230
27	TP53	NM_000546.6(TP53):c.701A>G (p.Tyr234Cys)	SNV	Likely Pathogenic	127820	rs587780073	GRCh37: 17:7577580-7577580 GRCh38: 17:7674262-7674262
28	TP53	NM_000546.6(TP53):c.638G>A (p.Arg213Gln)	SNV	Likely Pathogenic	135359	rs587778720	GRCh37: 17:7578211-7578211 GRCh38: 17:7674893-7674893
29	TP53	NM_000546.6(TP53):c.824G>C (p.Cys275Ser)	SNV	Likely Pathogenic	376583	rs863224451	GRCh37: 17:7577114-7577114 GRCh38: 17:7673796-7673796
30	TP53	NM_000546.6(TP53):c.536A>G (p.His179Arg)	SNV	Likely Pathogenic	376606	rs1057519991	GRCh37: 17:7578394-7578394 GRCh38: 17:7675076-7675076
31	TP53	NM_000546.6(TP53):c.731G>A (p.Gly244Asp)	SNV	Likely Pathogenic	372785	rs985033810	GRCh37: 17:7577550-7577550 GRCh38: 17:7674232-7674232
32	TP53	NM_000546.6(TP53):c.845G>A (p.Arg282Gln)	SNV	Likely Pathogenic	237956	rs730882008	GRCh37: 17:7577093-7577093 GRCh38: 17:7673775-7673775
33	TP53	NM_000546.6(TP53):c.536A>T (p.His179Leu)	SNV	Likely Pathogenic	376608	rs1057519991	GRCh37: 17:7578394-7578394 GRCh38: 17:7675076-7675076
34	TP53	NM_000546.6(TP53):c.746G>C (p.Arg249Thr)	SNV	Likely Pathogenic	376015	rs587782329	GRCh37: 17:7577535-7577535 GRCh38: 17:7674217-7674217
35	TP53	NM_000546.6(TP53):c.797G>T (p.Gly266Val)	SNV	Likely Pathogenic	233303	rs193920774	GRCh37: 17:7577141-7577141 GRCh38: 17:7673823-7673823
36	TP53	NM_000546.6(TP53):c.844C>T (p.Arg282Trp)	SNV	Likely Pathogenic	12364	rs28934574	GRCh37: 17:7577094-7577094 GRCh38: 17:7673776-7673776
37	TP53	NM_000546.6(TP53):c.842A>T (p.Asp281Val)	SNV	Likely Pathogenic	182968	rs587781525	GRCh37: 17:7577096-7577096 GRCh38: 17:7673778-7673778
38	TP53	NM_000546.6(TP53):c.713G>C (p.Cys238Ser)	SNV	Likely Pathogenic	376575	rs730882005	GRCh37: 17:7577568-7577568 GRCh38: 17:7674250-7674250
39	TP53	NM_000546.6(TP53):c.613T>C (p.Tyr205His)	SNV	Likely Pathogenic	376685	rs1057520008	GRCh37: 17:7578236-7578236 GRCh38: 17:7674918-7674918
40	TP53	NM_000546.6(TP53):c.658T>A (p.Tyr220Asn)	SNV	Likely Pathogenic	376688	rs530941076	GRCh37: 17:7578191-7578191 GRCh38: 17:7674873-7674873
41	TP53	NM_000546.6(TP53):c.725G>T (p.Cys242Phe)	SNV	Likely Pathogenic	376578	rs121912655	GRCh37: 17:7577556-7577556 GRCh38: 17:7674238-7674238
42	TP53	NM_000546.6(TP53):c.844C>G (p.Arg282Gly)	SNV	Likely Pathogenic	140821	rs28934574	GRCh37: 17:7577094-7577094 GRCh38: 17:7673776-7673776
43	TP53	NM_000546.6(TP53):c.583A>T (p.Ile195Phe)	SNV	Likely Pathogenic	376617	rs942158624	GRCh37: 17:7578266-7578266 GRCh38: 17:7674948-7674948
44	TP53	NM_000546.6(TP53):c.764T>A (p.Ile255Asn)	SNV	Likely Pathogenic	232289	rs876659675	GRCh37: 17:7577517-7577517 GRCh38: 17:7674199-7674199
45	TP53	NM_000546.6(TP53):c.733G>T (p.Gly245Cys)	SNV	Likely Pathogenic	12349	rs28934575	GRCh37: 17:7577548-7577548 GRCh38: 17:7674230-7674230
46	BRAF	NM_004333.6(BRAF):c.1799T>A (p.Val600Glu)	SNV	Likely Pathogenic	13961	rs113488022	GRCh37: 7:140453136-140453136 GRCh38: 7:140753336-140753336
47	PTEN	NM_000314.8(PTEN):c.698G>A (p.Arg233Gln)	SNV	Likely Pathogenic	376510	rs770025422	GRCh37: 10:89717673-89717673 GRCh38: 10:87957916-87957916
48	TP53	NM_000546.6(TP53):c.734G>C (p.Gly245Ala)	SNV	Likely Pathogenic	265357	rs121912656	GRCh37: 17:7577547-7577547 GRCh38: 17:7674229-7674229
49	TP53	NM_000546.6(TP53):c.734G>T (p.Gly245Val)	SNV	Likely Pathogenic	376603	rs121912656	GRCh37: 17:7577547-7577547 GRCh38: 17:7674229-7674229
50	TP53	NM_000546.6(TP53):c.646G>T (p.Val216Leu)	SNV	Likely Pathogenic	376670	rs730882025	GRCh37: 17:7578203-7578203 GRCh38: 17:7674885-7674885

Sources

Expression for Giant Cell Glioblastoma

Search GEO for disease gene expression data for Giant Cell Glioblastoma.

Sources

Pathways for Giant Cell Glioblastoma

Pathways related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

(show top 50) (show all 136)

#	Super pathways	Score	Top Affiliating Genes
1	Apoptotic Pathways in Synovial Fibroblasts ⁶⁴ Show member pathways Actin-Based Motility by Rho Family GTPases ⁶⁴ Cellular Apoptosis Pathway ⁶⁴ DHA Signaling ⁶⁴ eIF2 Pathway ⁶⁴ ERK5 Signaling ⁶⁴ Glioma Invasiveness ⁶⁴ Mitochondrial Apoptosis ⁶⁴ Nuclear Receptor Activation by Vitamin-A ⁶⁴ p53 Mediated Apoptosis ⁶⁴ PPAR Pathway ⁶⁴ Rac1 Pathway ⁶⁴ Rap1 Pathway ⁶⁴ Telomerase Components in Cell Signaling ⁶⁴	13.94	ATM BRAF EGFR FGFR1 FGFR3 H3-3A
2	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.91	TP53 PTEN PIK3R1 HRAS H3-3A FGFR3
3	Signal Transduction ⁶⁶	13.84	BRAF EGFR FGFR1 FGFR3 H3-3A HRAS
4	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.81	TP53 PTEN PIK3R1 PIK3CA MSH2 IDH1
5	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.63	TP53 PIK3R1 PIK3CA HRAS H3-3A FGFR3
6	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.49	TP53 PTEN PIK3R1 HRAS FGFR3 FGFR1
7	RAF/MAP kinase cascade ⁶⁶ Show member pathways Diseases of signal transduction by growth factor receptors and second messengers ⁶⁶ MAPK family signaling cascades ⁶⁶ MAPK1/MAPK3 signaling ⁶⁶	13.47	PTEN PIK3R1 PIK3CA HRAS FGFR3 FGFR1
8	Prolactin Signaling ⁶⁴ Show member pathways Development Prolactin receptor signaling ²² EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ⁷⁴ ErbB Family Pathway ⁶⁴ ErbB signaling pathway ⁷⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ ErbB4 Pathway ⁶⁴ Estrogen-stimulated signaling through PRKCZ ⁶⁶ Glioblastoma Multiforme ⁶⁴ Glioblastoma signaling pathways ⁷⁴ Growth Hormone Signaling ⁶⁴ HMGB1 Pathway ⁶⁴ IL-2 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ TCA cycle nutrient use and invasiveness of ovarian cancer ⁷⁴ Thrombopoietin Pathway ⁶⁴ TREM1 Pathway ⁶⁴ UVA-Induced MAPK Signaling ⁶⁴ UVB-Induced MAPK Signaling ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	13.42	TP53 PTEN PIK3R1 PIK3CA MGMT HRAS
9	PIP3 activates AKT signaling ⁶⁶ Show member pathways Intracellular signaling by second messengers ⁶⁶ PTEN Regulation ⁶⁶ Regulation of PTEN gene transcription ⁶⁶ Regulation of PTEN localization ⁶⁶	13.16	EGFR FGFR1 FGFR3 PIK3CA PIK3R1 PTEN
10	Phospholipase-C Pathway ⁶⁴ Show member pathways PTEN Pathway ⁶⁴	13.16	BRAF EGFR FGFR1 FGFR3 HRAS PIK3R1
11	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	13.03	TP53 PTEN PIK3R1 PIK3CA HRAS FGFR3
12	TNFR1 Pathway ⁶⁴ Show member pathways Apoptosis ⁷⁴ Apoptosis and survival TNFR1 signaling pathway ²² Apoptosis modulation by HSP70 ⁷⁴ Apoptosis through Death Receptors ⁶⁴ Apoptotic Pathways Triggered By HIV1 ⁶⁴ Ceramide signaling pathway ⁶¹ DR3 Signaling ⁶⁴ GITR Pathway ⁶⁴ HIV-1 Nef: Negative effector of Fas and TNF-alpha ⁶¹ Stimulation of the cell death response by PAK-2p34 ⁶⁶ TNF Signaling ⁶⁴ TNF-related weak inducer of apoptosis (TWEAK) signaling pathway ⁷⁴ TRAIL Pathway ⁶⁴ TWEAK Pathway ⁶⁴	13.02	EGFR HRAS PIK3CA PIK3R1 PTEN TP53
13	IL-9 Signaling Pathways ⁶⁵ Show member pathways Adipocytokines and Insulin Signaling ⁶⁵ Common Cytokine Receptor Gamma-Chain Family Signaling Pathways ⁶⁵ Development Thrombopoietin-regulated cell processes ²² IL-15 Signaling Pathways ⁶⁵ IL-2 Signaling Pathways ⁶⁵ IL-21 Signaling Pathways ⁶⁵ IL-4 Pathway ⁶⁴ IL-4 Signaling Pathways ⁶⁵ IL-7 Signaling Pathways ⁶⁵ IL-9 Pathway ⁶⁴ Immune response IL-9 signaling pathway ²² Interleukin-9 signaling ⁶⁶	12.94	PTEN PIK3R1 PIK3CA HRAS BRAF
14	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.93	TP53 PIK3R1 PIK3CA HRAS BRAF
15	Development Angiotensin activation of ERK ²² Show member pathways Cell adhesion Integrin inside-out signaling ²² Development ACM2 and ACM4 activation of ERK ²² Development Angiotensin signaling via PYK2 ²² Development EDNRB signaling ²² Development EPO-induced MAPK pathway ²² Development G-Proteins mediated regulation MARK-ERK signaling ²² Signal transduction IP3 signaling ²²	12.93	PIK3R1 PIK3CA HRAS EGFR BRAF
16	NFAT and Cardiac Hypertrophy ⁶⁴ Show member pathways IGF1R Signaling ⁶⁴ Signaling Involved in Cardiac Hypertrophy ⁶⁴	12.93	PTEN PIK3R1 PIK3CA HRAS FGFR3 FGFR1
17	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.88	BRAF EGFR FGFR1 FGFR3 HRAS MYCN
18	Translation Insulin regulation of translation ²² Show member pathways Butyrate-induced histone acetylation ⁷⁴ Cell adhesion PLAU signaling ²² Development CNTF receptor signaling ²² Development Growth hormone signaling via PI3K/AKT and MAPK cascades ²² Overview of perturbations to host-cell autophagy, induced by distinct proteins of SARS-CoV-2 ⁷⁴ Regulation of lipid metabolism Insulin signaling-generic cascades ²² Transcription Receptor-mediated HIF regulation ²² Translation Regulation of EIF2 activity ²² Translation Regulation of EIF4F activity ²² Translation inhibitors in chronically activated PDGFRA cells ⁷⁴	12.84	PTEN PIK3R1 PIK3CA HRAS EGFR
19	Insulin receptor signalling cascade ⁶⁶ Show member pathways Glucose homeostasis ⁷⁴ IGF1R signaling cascade ⁶⁶ IRS activation ⁶⁶ IRS-mediated signalling ⁶⁶ IRS-related events triggered by IGF1R ⁶⁶ PI3K Cascade ⁶⁶ SHC-related events triggered by IGF1R ⁶⁶ Signal attenuation ⁶⁶ Signaling by Insulin receptor ⁶⁶ Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) ⁶⁶ SOS-mediated signalling ⁶⁶	12.8	PIK3R1 PIK3CA HRAS FGFR3 FGFR1
20	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ⁶⁶ Show member pathways Constitutive Signaling by Aberrant PI3K in Cancer ⁶⁶ Negative regulation of the PI3K/AKT network ⁶⁶ PI3K/AKT Signaling in Cancer ⁶⁶	12.79	PTEN PIK3R1 PIK3CA FGFR3 FGFR1 EGFR
21	4-1BB Pathway ⁶⁴ Show member pathways CD27 Pathway ⁶⁴ CD40 Signaling ⁶⁴ CMV and MAPK Pathways ⁶⁴ NF-KappaB Activation by EBV ⁶⁴ NF-kappaB Activation by Viruses ⁶⁴ PKR Pathway ⁶⁴ SUMO Pathway ⁶⁴ TNFR2 Pathway ⁶⁴	12.76	TP53 PIK3R1 HRAS EGFR BRAF
22	Malignant pleural mesothelioma ⁷⁴	12.74	TP53 PTEN PIK3CA HRAS FGFR3 FGFR1
23	Chks in Checkpoint Regulation ⁶⁴ Show member pathways DNA Repair Mechanisms ⁶⁴ Estrogen-mediated S-Phase Entry ⁶⁴ G2-M Phase Transition ⁶⁴ SREBP Proteolysis ⁶⁴	12.71	TP53 POLE MSH2 MGMT ATM
24	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.71	ATM EGFR FGFR1 FGFR3 HRAS PIK3CA
25	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.7	EGFR HRAS MSH2 PIK3CA PIK3R1 TP53
26	Negative regulation of FGFR1 signaling ⁶⁶ Show member pathways FGFR1 ligand binding and activation ⁶⁶ FGFR1b ligand binding and activation ⁶⁶ FGFR1c and Klotho ligand binding and activation ⁶⁶ FGFR1c ligand binding and activation ⁶⁶ FGFRL1 modulation of FGFR1 signaling ⁶⁶ Negative regulation of FGFR2 signaling ⁶⁶ Negative regulation of FGFR3 signaling ⁶⁶ Negative regulation of FGFR4 signaling ⁶⁶ Signaling by activated point mutants of FGFR1 ⁶⁶ Signaling by FGFR1 ⁶⁶ Signaling by FGFR1 amplification mutants ⁶⁶ Signaling by FGFR3 ⁶⁶ Signaling by FGFR4 ⁶⁶ Spry regulation of FGF signaling ⁶⁶	12.69	PIK3R1 PIK3CA HRAS FGFR3 FGFR1 BRAF
27	DNA Damage ³	12.62	TP53 TACC3 MSH2 MGMT ATM
28	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.59	TP53 PIK3R1 PIK3CA HRAS EGFR BRAF
29	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.57	TP53 PTEN PIK3R1 PIK3CA HRAS BRAF
30	Development FGFR signaling pathway ²² Show member pathways Development FGF-family signaling ²² Development Flt3 signaling ²² FGF Pathway ⁶⁴	12.52	PIK3R1 PIK3CA HRAS FGFR3 FGFR1
31	RhoGDI Pathway ⁶⁴ Show member pathways Fc-GammaR-Mediated Phagocytosis in Macrophages ⁶⁴	12.51	PIK3R1 HRAS FGFR3 FGFR1 EGFR
32	MAPK signaling pathway ⁷⁴	12.5	BRAF EGFR FGFR1 FGFR3 HRAS TP53
33	Development Dopamine D2 receptor transactivation of EGFR ²² Show member pathways Chemotaxis CXCR4 signaling pathway ²² Development Alpha-2 adrenergic receptor activation of ERK ²² Extra-nuclear estrogen signaling ⁶⁶	12.49	PIK3R1 PIK3CA HRAS EGFR
34	Development VEGF signaling via VEGFR2 - generic cascades ²² Show member pathways Development VEGF signaling and activation ²² VEGF - VEGF R2 Signaling Pathways ⁶⁵	12.49	PIK3R1 PIK3CA HRAS BRAF
35	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.49	PIK3R1 PIK3CA HRAS FGFR3 FGFR1 EGFR
36	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.47	TP53 PTEN PIK3R1 PIK3CA MSH2 HRAS
37	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.45	TP53 PIK3R1 PIK3CA HRAS FGFR3 FGFR1
38	Immune response Fc epsilon RI pathway ²² Show member pathways Fc-epsilon receptor I signaling in mast cells ⁶¹ Immune response BCR pathway ²²	12.43	PTEN PIK3R1 PIK3CA HRAS
39	Development Ligand-independent activation of ESR1 and ESR2 ²² Show member pathways Transcription CREB pathway ²² Transcription PPAR Pathway ²²	12.42	PIK3R1 PIK3CA HRAS EGFR
40	Toll Comparative Pathway ⁶⁴ Show member pathways IL-1 Pathway ⁶⁴ Immune response MIF in innate immunity response ²² iNOS Signaling ⁶⁴ TLR-TRIF Pathway ⁶⁴	12.42	TP53 PIK3R1 PIK3CA HRAS FGFR1
41	B Cell Receptor Signaling Pathway ⁶⁷ Show member pathways T Cell Receptor Signaling Pathway ⁶⁷	12.41	PTEN PIK3R1 PIK3CA HRAS
42	PDGFR-beta signaling pathway ⁶¹ Show member pathways ErbB1 downstream signaling ⁶¹	12.38	BRAF EGFR PIK3CA PIK3R1 PTEN
43	Focal adhesion ⁷⁴	12.38	PTEN PIK3R1 PIK3CA HRAS EGFR BRAF
44	Development IGF-1 receptor signaling ²² Show member pathways Immune response IL-4 signaling pathway ²² Signal transduction AKT signaling ²²	12.37	TP53 PTEN PIK3R1 PIK3CA HRAS
45	Signaling by FGFR2 ⁶⁶ Show member pathways FGFR2 ligand binding and activation ⁶⁶ FGFR2b ligand binding and activation ⁶⁶ Signaling by FGFR ⁶⁶	12.36	BRAF FGFR1 FGFR3 HRAS PIK3CA PIK3R1
46	Development Endothelin-1/EDNRA transactivation of EGFR ²² Show member pathways Cytoskeleton remodeling FAK signaling ²² Development Endothelin-1/EDNRA signaling ²²	12.35	PIK3R1 PIK3CA HRAS EGFR
47	Signaling by ERBB2 KD Mutants ⁶⁶ Show member pathways Constitutive Signaling by Overexpressed ERBB2 ⁶⁶ GRB2 events in ERBB2 signaling ⁶⁶ PI3K events in ERBB2 signaling ⁶⁶ PI3K events in ERBB4 signaling ⁶⁶ PLCG1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB4 signaling ⁶⁶ Signaling by ERBB2 ECD mutants ⁶⁶ Signaling by ERBB2 in Cancer ⁶⁶ Signaling by ERBB2 TMD/JMD mutants ⁶⁶	12.34	PIK3R1 PIK3CA HRAS EGFR
48	VEGF Signaling Pathway ⁶⁰ ⁶⁷ Show member pathways Nanoparticle-mediated activation of receptor signaling ⁷⁴ TGF-beta Signaling ⁶⁷	12.33	PTEN HRAS FGFR3 FGFR1 EGFR
49	Ras signaling ⁷⁴	12.32	EGFR FGFR1 FGFR3 HRAS PIK3CA PIK3R1
50	Colorectal Cancer Metastasis ⁶⁴	12.31	TP53 PIK3R1 MSH2 EGFR BRAF

Sources

GO Terms for Giant Cell Glioblastoma

Biological processes related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

(show all 13)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of ERK1 and ERK2 cascade	GO:0070374	10.13	PTEN HRAS FGFR3 EGFR BRAF
2	negative regulation of neuron apoptotic process	GO:0043524	10.1	PIK3CA MSH2 HRAS BRAF
3	regulation of cell cycle	GO:0051726	10.06	TP53 PTEN MSH2 HRAS ATM
4	epidermal growth factor receptor signaling pathway	GO:0007173	9.99	PIK3CA EGFR BRAF
5	phosphatidylinositol 3-kinase signaling	GO:0014065	9.95	PIK3CA PIK3R1 PTEN
6	cell population proliferation	GO:0008283	9.91	TP53 TACC3 TACC1 PTEN EGFR
7	cellular response to gamma radiation	GO:0071480	9.88	ATM HRAS TP53
8	MAPK cascade	GO:0000165	9.85	HRAS FGFR3 FGFR1 EGFR BRAF
9	determination of adult lifespan	GO:0008340	9.73	TP53 MSH2 ATM
10	phosphorylation	GO:0016310	9.56	PIK3R1 PIK3CA FGFR3 FGFR1 EGFR BRAF
11	regulation of axon regeneration	GO:0048679	9.52	PTEN BRAF
12	cellular response to endogenous stimulus	GO:0071495	9.32	FGFR3 FGFR1
13	positive regulation of miRNA maturation	GO:1903800	8.92	TP53 MYCN EGFR

Molecular functions related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	transferase activity	GO:0016740	9.86	POLE PIK3CA MGMT FGFR3 FGFR1 EGFR
2	protein tyrosine kinase activity	GO:0004713	9.7	BRAF EGFR FGFR1 FGFR3
3	fibroblast growth factor receptor activity	GO:0005007	9.62	FGFR3 FGFR1
4	kinase activity	GO:0016301	9.56	PIK3R1 PIK3CA FGFR3 FGFR1 EGFR BRAF
5	protein serine/threonine kinase activator activity	GO:0043539	9.54	PIK3R1 PIK3CA HRAS
6	nucleotide binding	GO:0000166	9.36	SEPTIN14 POLE PIK3CA MSH2 HRAS FGFR3